Infasurf

calfactant

Infasurf

Pharmacologic class: Natural lung surfactant

Therapeutic class: Lung surfactant

Pregnancy risk category NR

Action

Adsorbs rapidly to air: liquid interface of lung alveoli, stabilizing and modifying surface tension. Restores adequate pressure volumes, gas exchange, and overall lung compliance.

Availability

Suspension for intratracheal injection: 6 ml in single-dose vials

Indications and dosages

To prevent respiratory distress syndrome (RDS) in at-risk premature infants; treatment of infants who develop RDS

Premature infants: 3 ml/kg at birth intratracheally q 12 hours, up to three doses. Initial dose must be administered as two 1.5-ml/kg doses.

Contraindications

None

Precautions

Use cautiously in:
• altered ventilation requirements
• risk of cyanosis, bradycardia, or airway obstruction.

Administration

Know that drug is intended for intratracheal administration and should be given only by neonatologists or other clinicians experienced in neonatal intubation and ventilatory management in facilities with adequate personnel, equipment, and drugs.

Don't dilute drug or shake vial.
• Be aware that drug must be drawn into syringe through 20G or larger needle, taking care to avoid excessive foaming. Needle must be removed before drug is delivered through endotracheal tube.

Know that infant must receive continuous monitoring before, during, and after drug administration.

Adverse reactions

CV: bradycardia

Respiratory: requirement for manual ventilation or reintubation, airway obstruction, reflux of drug into endotracheal tube, cyanosis

Interactions

None significant

Patient monitoring

Monitor infant's respiratory status continuously during and after drug administration.

Patient teaching

• Teach parents about treatment and assure them that infant will be monitored carefully.

Infasurf®

Calfactant Neonatology A suspension administered intratracheally to prevent RDS in high-risk premature infants < 29 wks of gestational age who require endotracheal intubation. See Respiratory distress syndrome.
Mentioned in ?
References in periodicals archive ?
Curosurf Poractant alpha Alveofact SF-RI 1 BLES Bovine Lipid Extract Surfactant Infasurf Calfactant CLSE Newfacten ?
The independent analysis, which was published in the eFirst Pages section of the Pediatrics website, was aimed at comparing the efficacy of CUROSURF versus Survanta (beractant) and Infasurf (calfactant) with respect to clinical outcomes among preterm infants with RDS.
De acuerdo con los datos encontrados en los recien nacidos menores de 1500 gramos, el surfactante cuyos pacientes presentaron un menor porcentaje de displasia fue el survanta con un 66%, seguido por el curosurf con un 70% y el infasurf con un 75%.
El curosurf y el infasurf obtuvieron un 50% cada uno.
The biological surfactant preparation Infasurf (calfactant) was a natural lung-ravage surfactant derived from calf lung that required no reconstitution.
Medications administered during the weeks of testing consisted of caffeine, ampicillin, gentamicin, and Infasurf.
Four large (several hundred in each group), prospective randomized clinical trials comparing Exosurf (synthetic, no apoproteins) to Survanta (beractant) and to Infasurf (calfactant) have been conducted.
To date, large randomized clinical trials of Survanta and Infasurf have identified no differences in mortality between surfactants with apoproteins.
Overall, CUROSURF treatment for RDS was associated with a significantly reduced likelihood of death compared to Infasurf, and a trend toward reduced mortality when compared with Survanta.
5 December 2011 - ONY Inc, the producer of Infasurf which is used to treat premature infants against Respiratory Distress Syndrome, filed a lawsuit against Cornerstone Therapeutics (NASDAQ:CRTX) and its parent firm, Chiesi Farmaceutici SpA, of providing manipulated data to claim the use of its competing drug, Curosurf, leads to lower mortality rates.
There was no difference in mortality when surfactants Infasurf and Survanta were used in neonates less than 36 weeks' estimated gestation, reported Dr.
Samaritan has distribution rights to sell specialty pharmaceutical products such as, Amphocil from Three Rivers Pharmaceuticals, Elaprase and Replagal from Shire Pharmaceuticals, Infasurf from Ony, Inc, Erwinase, Kidrolase, and the Rapydan pain patch from EUSA, Mepivamol, Methadone, Morphine Sulphate, Naloxone, Naltrexone, Oramorph and Pethidine from Molteni Farmaceutici and Abioklad from Abiogen Pharma.